Karen L. Smith

Insider Reports History

Location
Dublin L2 4, Ireland
Signature
/s/ Kaitlyn Arsenault, as Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Karen L. Smith:

Company Role Class Num Shares Value Price $ Report Date Ownership
Aurinia Pharmaceuticals Inc. Director Common Shares 24,807 $209,123 $8.43 21 Nov 2024 Direct
SANGAMO THERAPEUTICS, INC Director Common Stock 102,100 $46,966 $0.4600 12 Jun 2025 Direct
Emergent BioSolutions Inc. EVP, Chief Medical Officer Common Stock 11,888 $21,636 $1.82 07 May 2021 Direct
Quince Therapeutics, Inc. Chief Medical Officer Employee Stock Option (right to buy) 225,000 01 Feb 2023 Direct
Context Therapeutics Inc. Director Stock Option (right to buy) 123,500 12 Jun 2025 Direct
SANGAMO THERAPEUTICS, INC Director Stock Option (Right to Buy) 50,000 12 Jun 2025 Direct
Skye Bioscience, Inc. Director Stock Option (Right to Buy) 35,000 06 Feb 2026 Direct
Talaris Therapeutics, Inc. Director Stock Option (Right to Buy) 20,500 13 Jun 2023 Direct
Aurinia Pharmaceuticals Inc. Director Director Stock Option (right to buy) 18,641 21 Nov 2024 Direct
ACCELERON PHARMA INC Director Common Stock 0 $29.37 19 Nov 2021 Direct
ACCELERON PHARMA INC Director Option to Purchase Common Stock 0 19 Nov 2021 Direct
ANTARES PHARMA, INC. Director Common Stock 0 $5.60 24 May 2022 Direct
ANTARES PHARMA, INC. Director Stock Option (right to buy) 0 24 May 2022 Direct
Aurinia Pharmaceuticals Inc. Director Restricted Stock Units 0 08 Nov 2024 Direct

Insider Reports Filed by Karen L. Smith

Symbol Company Period Transactions Value $ Form Type Role Filing Time
SKYE Skye Bioscience, Inc. 06 Feb 2026 1 $0 4 Director 09 Feb 2026, 20:54
SGMO SANGAMO THERAPEUTICS, INC 12 Jun 2025 2 $0 4 Director 16 Jun 2025, 16:05
CNTX Context Therapeutics Inc. 12 Jun 2025 1 $0 4 Director 12 Jun 2025, 17:27
SKYE Skye Bioscience, Inc. 24 Feb 2025 1 $0 4 Director 26 Feb 2025, 17:45
AUPH Aurinia Pharmaceuticals Inc. 21 Nov 2024 2 $0 4 Director 25 Nov 2024, 16:38
AUPH Aurinia Pharmaceuticals Inc. 08 Nov 2024 3 -$44,182 4 Director 12 Nov 2024, 19:20
SKYE Skye Bioscience, Inc. 28 Oct 2024 1 $0 4 Director 30 Oct 2024, 20:28
CNTX Context Therapeutics Inc. 04 Sep 2024 1 $0 4 Director 05 Sep 2024, 08:15
CNTX Context Therapeutics Inc. 04 Sep 2024 0 $0 3 Director 05 Sep 2024, 08:08
SKYE Skye Bioscience, Inc. 02 Jul 2024 1 $0 4 Director 05 Jul 2024, 08:59
SKYE Skye Bioscience, Inc. 02 Jul 2024 0 $0 3 Director 05 Jul 2024, 08:58
SGMO SANGAMO THERAPEUTICS, INC 04 Jun 2024 2 $0 4 Director 06 Jun 2024, 16:26
AUPH Aurinia Pharmaceuticals Inc. 18 Aug 2023 2 $0 4 Director 21 Aug 2023, 16:19
AUPH Aurinia Pharmaceuticals Inc. 18 Aug 2023 0 $0 3 Director 21 Aug 2023, 16:16
TRML Talaris Therapeutics, Inc. 13 Jun 2023 1 $0 4 Director 14 Jun 2023, 19:02
SGMO SANGAMO THERAPEUTICS, INC 01 Jun 2023 2 $0 4 Director 05 Jun 2023, 16:52
QNCX Quince Therapeutics, Inc. 01 Feb 2023 1 $0 4 Chief Medical Officer 02 Feb 2023, 17:35
TRML Talaris Therapeutics, Inc. 09 Jun 2022 1 $0 4 Director 13 Jun 2022, 18:16
/report/000089924322019793-smith-karen-l-2022-05-24 ANTARES PHARMA, INC. 24 May 2022 6 -$446,012 4 Director 26 May 2022, 17:26
QNCX Cortexyme, Inc. 19 May 2022 1 $0 4/A Chief Medical Officer 27 May 2022, 17:37
QNCX Cortexyme, Inc. 19 May 2022 0 $0 3 Chief Medical Officer 23 May 2022, 20:22
TRML Talaris Therapeutics, Inc. 16 May 2022 1 $0 4 Director 17 May 2022, 18:15
TRML Talaris Therapeutics, Inc. 16 May 2022 0 $0 3 Director 17 May 2022, 18:12
SGMO SANGAMO THERAPEUTICS, INC 25 Feb 2022 2 $0 4 Director 01 Mar 2022, 16:14
/report/000110465921142277-smith-karen-l-2021-11-19 ACCELERON PHARMA INC 19 Nov 2021 6 $0 4 Director 22 Nov 2021, 08:09
/report/000120919121040340-smith-karen-l-2021-06-10 ANTARES PHARMA, INC. 10 Jun 2021 2 +$112,498 4 Director 14 Jun 2021, 18:27
EBS Emergent BioSolutions Inc. 07 May 2021 1 -$18,559 4 EVP, Chief Medical Officer 11 May 2021, 16:30